Kailera Therapeutics
United States · Biotech · Healthtech
Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms.
Product
Kailera is a clinical-stage biopharmaceutical company developing a portfolio of obesity treatments. Its four clinical-stage candidates combine different GLP-1-based mechanisms with oral and injectable delivery, aiming to give patients and clinicians a broader range of treatment options.
Its lead program, ribupatide injection, is a dual GLP-1/GIP receptor agonist in a global Phase 3 program. Kailera also develops oral therapies and other multi-receptor approaches, building its pipeline around different needs within obesity care.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $600M | Bain Capital Private Equity — LeadAdage Capital Management — ParticipantAtlas Venture — ParticipantBain Capital Life Sciences — ParticipantCanada Pension Plan Investment Board (CPP Investments) — ParticipantInvus — ParticipantJanus Henderson Investors — ParticipantPerseverance Capital — ParticipantQatar Investment Authority (QIA) — ParticipantRoyalty Pharma — ParticipantRTW Investments — ParticipantSirona Capital — ParticipantSurveyor Capital — ParticipantT. Rowe Price Associates Inc. — Participant |